ISAMOXOLE is an effective anti-allergic compound in animals. It is a moderately potent, selective inhibitor of slow-reacting substance of anaphylaxis (SRS-A) activity. SRS-A is a group of leukotrienes (LTC4, LTD4, and LTE4) that is the major mediator of bronchoconstriction, hypersensitivity, and other allergic reactions.

FILIPIN is a complex of polyene macrolides obtained from Streptomyces filipinensis. The complex consists of four components: filipin I (4%), II (25%), III (53%), and IV (18%). Filipin III alters membrane function by interfering with membrane sterols, inhibits mitochondrial respiration, and is proposed as an antifungal agent. It is widely used as a marker for detection and quantification of cholesterol in cellular membranes.

Triclonide is the anti-inflammatory steroid for the topical use.

Ripazepam (CI 683 or pyrazapon) is a pyrazolodiazepine that has anxiolytic effects. It is related to certain benzodiazepines such as zolazepam. In animal studies, it showed anxiolytic effects without sedative or depressant effects. In rats, it did not elicit a tumorigenic potential. Although ripazepam was found significantly superior to placebo and was well tolerated in neurotic patients, it has never been marketed for clinical use.

Disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended. Technetium Tc 99m disofenin injection is a radiopharmaceutical. Technetium Tc99m disofenin is indicated as a hepatobiliary imaging agent. Technetium Tc99m disofenin is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms. Itching at the site of injection progressing to erythema multiforme has been reported following single administration. Also, rare cases of chills and nausea have been reported.

Hexedine has been used as an antimicrobial agent and drug constituent. Information about the current use of this drug is not available.

Letimide is a new analgesic. It is a cyclic derivative of a salicylamide. The analgesic effect of this drug as determined in rats showed a higher potency than aspirin, but was without anti-inflammatory and antipyretic activity. Letimide is not a genotoxic agent according to the cytogenetic damage observed in vivo and in vitro, and would seem to justify other preclinical and clinical studies to confirm its lack of toxicity. Known adverse effects are headache and dizziness.

Delmadinone is a steroid with progestogenic, anti-androgenic and weak glucocorticoid action, synthesized in Syntex S.A. Acetate ester of delmadinone is used in veterinary under tradenames Tardak for cats and dogs for the treatment of excessive or aberrant sexual behaviour, including vagrancy, for the relief of prostatic hypertrophy, circum-anal tumors and for the treatment of certain forms of aggressiveness, nervousness, epileptiform seizures and corticosteroid-resistant pruritus. Delmadinone acetate blocks androgen receptors inhibit 5-reductase, which catalyzes the transformation of testosterone to the more potent androgen 5-dihydrotestosterone and decreases the production of testosterone by inhibiting gonadotropin release.

Iosimide is synthetic, nonionic, monomeric contrast medium patented by Schering A.-G. In clinical trial Iosimide exhibited no differences in comparison with Ioxaglate with respect to the contrast, the neurological status or the liver or renal tolerance. In examining cardiovascular tolerance there is only a slight tendency toward liver changes with Iosimide. Examination of the general tolerance, however, shows a statistically significant lower incidence of sensation of heat and pain with iosimide than with ioxaglate.

BMS 599626 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM. BMS-599626 is identified as an ATP-competitive inhibitor for HER1 and as an ATP-noncompetitive inhibitor for HER2. BMS-599626 inhibits the proliferation of tumor cells expressing high levels of HER1 and/or HER2, including Sal2, BT474, N87, KPL-4, HCC202, HCC1954, HCC1419, AU565, ZR-75-30, MDA-MB-175, GEO, and PC9 cells. In a phase I trial of solid tumour patients receiving BMS 599626 no doselimiting toxicities were observed during the first cycle. Grade 1 or 2 drugrelated effects were reported and included diarrhoea, nausea, vomiting, rash, fatigue, musculoskeletal pain/cramp and cough. BristolMyers Squibb discontinued development of BMS 599626 for cancer in July 2015